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Background: Huachansu (HCS), a class of toxic steroids extracted from toad venom, which has been shown to be a
valuable anticancer drug in many kinds of cancers. However, the effect of HCS on bladder cancer has not been
elucidated. In this study, we focused on the antitumor activities and related mechanisms of HCS on bladder cancer
in vitro and in vivo.
Methods: Cell viability of T24, EJ, RT-4, SV-HUC-1 cells after HCS treatment was measured by MTS, whereas the
changes of cell morphology were observed by transmission electron microscopy. The early apoptosis induced by
HCS was evaluated by flow cytometry, and the expression level of apoptosis-related molecules (Bax, Bcl-2, XIAP,
PARP, cleaved-Caspases 3, 8, 9) was detected using Western blot. We then evaluated the impact of HCS on the
expression of Fas/Fasl, TNF- alpha/TNFR1, and the activation of NF-Kappa B pathway, and furthermore the effect of
these pathways in HCS induced-apoptosis were also detected. At last, xenograft tumor in nude mice was used to
further investigate the antitumor effect of HCS in vivo.
Results: Our results showed that HCS could efficiently inhibit proliferation and induce apoptosis in human bladder
cancer cell lines. The expression of Fas, Fasl, TNF- alpha were all elevated at both mRNA and protein level after HCS
treatment. Furthermore, down regulation of TNF- alpha, TNFR1, Fas or inhibition of Fas/Fasl interaction decreased
the relative number of death cells induced by HCS. In vivo, HCS treatment significantly suppressed tumor growth
and induced apoptosis in xenografts tumor in nude mice.
Conclusions: HCS could efficiently inhibit proliferation and induce apoptosis in human bladder cancer cells in vitro
and in vivo, which is largely mediated by Fas/Fasl and TNF- alpha/TNFR1 pathway.
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Bladder cancer is a major public health problem world-
wide. More than 90% of the bladder cancers are urothe-
lial cell carcinomas (UCC) and approximately 70% of
bladder tumor present as non-muscle-invasive bladder
cancer (NMIBC) [1,2]. The standard treatment for
patients with superficial bladder cancer is transurethral
resection (TUR) of tumors. However, nearly 60% to 70%* Correspondence: xuhuawhu@163.com; zhangqun_ye@163.com
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unless otherwise stated.of these tumors will recur, and 25% will progress into a
higher stage or grade [3,4]. Although many chemical
agents have shown some evidence of activity against
tumor recurrence, their toxicity and incomplete efficacy
have limited their use as common chemotherapy agents
[5]. These factors highlight the urgent of novel adjuvant
agents. Natural products, including those from plants
and microorganisms, provide much potential for anti-
cancer drug discovery [6,7].
Chansu, the dried toad venom or the dried secretion
from the skin glands of Bufo bufo gargarizans Cantor or
B.melanotictus Schneider has long been used for cancer
treatment in China and other Asian countries, such ashis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Huachansu (HCS) is an injectable form of chansu, the
extract contains several biologically active substances,
primarily indole alkaloids (bufotenine, bufotenidine, and
cinobufotenine) and steroidal cardiac glycosides (bufalin,
resibufogenin, cinobufagin, cinobufotalin, marinobufagin,
and bufotalin). Recent studies showed that the antitumor
activity of HCS can be attributed mainly to the cardiac
glycosides it contains, including bufalin, resibufogenin,
and cinobufagin. High-pressure liquid chromatography
(HPLC) analysis determined the relative concentrations of
the components. Bufalin was present at the highest con-
centration, followed by moderate levels of cinobufagin
[11]. Chansu extractions including Bufalin and cinobufa-
gin induce apoptosis and inhibit proliferation of many
cancer cells through different pathways, Bufalin induces
apoptosis by activation of activator protein-1 (AP-1), the
c-JunN-terminal protein kinase, Rac1, mitogen-activated
proteinkinase [9,12] in human leukemia U937 cells, as
well as by inhibition of phosphatidylinositol 3-kinase
(PI3K)/Akt signaling in human gastric cancer cells [13].
Bufalin and cinobufagin induce apoptosis of human pros-
tate cancer cells partialy with Fas stimulation, Bax trans-
location, cytochrome c release and caspase activation [14].
However, the effect of HCS on bladder cancer has not
been elucidated. So in this study, we investigated the anti-
cancer effects and related molecular mechanisms of HCS
on bladder cancer in vitro and in vivo.Methods
Cell culture and reagents
Bladder cancer cell lines T24 and EJ were obtained from
the Institute of Biochemistry and Cell Biology, Shanghai
Institutes for Biological Sciences, Chinese Academy of
Sciences (Shanghai, China), and maintained in RPMI-
1640 medium. SV-HUC-1 and RT-4 were also purchased
from this place and maintained in DMEM/F-12 and
McCoy's 5A medium respectively. Cells were cultured
added with 10% fetal bovine serum (FBS) in a humidified
atmosphere of 5% CO2 maintained at 37°C. HCS was ob-
tained from Anhui Jinchan Biochemistry Company Ltd.,
in Huaibei, China (Chinese FDA (Z34020274)), PDTC
was purchased from Sigma-Aldrich and ZB4 was bought
from GeneTex.Cell viability assay
Briefly, T24, EJ, RT-4 and SV-HUC-1 cells (3 × 103 per
well) were plated in 96-well plates and incubated with
various dilutions of standard HCS(1:400, 1:200, 1:100,
1:50) for 24, 48 and 72 h. Cell viability was then detected
using CellTiter 96®AQueous Non-Radioactive Cell Pro-
liferation Assay (MTS) (Promega, USA). Three inde-
pendent experiments with triplicate were carried out.Transmission electron microscopy
T24 cells were pretreated with the indicated dilution of
HCS(1:100) for 24 h and 48 h, respectively. The treated
cells were then collected and fixed with 2.5% glutaralde-
hyde. Ultrastructure of the cells was examined on a
transmission electron microscopy (Tecnai, Netherlands)
at 2500× magnification.
Flow cytometry
Cellular apoptosis was determined by annexin V-FITC/
PI staining using flow cytometry. T24 and EJ cells were
pretreated with different dilutions of HCS for 24 h. After
that, cells (1 × 106) were collected, centrifuged and
washed with phosphate buffered saline(PBS) for two
times. 300 μL Binding buffer was then added to each
tube and cells were re-suspended. The supernatant cells
were incubated with 5 μL of annexin V-FITC and 5 μL
of PI for 15 min at room temperature in the dark. Then,
the apoptotic analyses were done by flow cytometry
within one hour.
RNA extraction and quantitative real-time RT-PCR
Total RNA was extracted with the TRIzol reagent (Invi-
trogen Life Technologies). RNA yield and quality were
determined with a Nano Drop 1000 Spectrophotometer.
For cDNA synthesis, 1 μl of total RNA was reverse-
transcribed using Toyobo RT reagent Kit (Perfect Real
Time) according to the manufacturer’s instructions.
Quantitative real-time RT-PCR was carried out using
using SYBR Premix Ex Taq on MX3000 instrument. The
PCR amplification program consisted of an initial poly-
merase activation at 95°C for 10 min, followed by 40 cycles
at 95°C for 5 s, 60°C for 30 s and 72°C for 30 s for those
for genes. The results were normalized with housekeeping
gene Beta-actin. Sequences of primers are listed in
Table 1.
Protein extraction and Western blot analysis
Cells after treated with HCS were harvested and lysed
with lysis buffer (50 mM Tris (pH7.4), 50 mM NaCl,
1 mM EDTA, 1% Triton X-100, and 10% glycerol). All
solutions contains protease inhibitor cocktail (Sigma)
and mixture of phosphatase inhibitors (10 mM NaF,
1 mM sodium pyrophosphate, 1 mM sodium orthovana-
date, and 0.1 mM β- glycerophosphate), and the protein
extraction was processed according to the manufactur-
er's instructions. Protein concentration was measured
using a BCA Protein Assay Kit (Beyotime, Wuhan,
China) according to the manufacturer's instructions. For
Western blot analysis, an equal amounts of 50 μg protein
were subjected to electrophoresis on SDS-polyacrylamide
gels and transferred onto polyvinylidene fluoride (PVDF)
transfer membranes by western blotting. Blots were
probed with the following antibodies Bax, Bcl-2, XIAP,
Table 1 Primer sequences for RT-PCR
Target Upstream primer Downstream primer Accession number
Fas TCTGGTTCTTACGTCTGTTGC CTGTGCAGTCCCTAGCTTTCC NM_152872
Fasl AACTCAAGGTCCATGCCTCTG GGTGAGTTGAGGAGCTACAGACA NM_000639
TNF-α TGTAGCCCATGTTGTAGCAAA CAAAGTAGACCTGCCCAGACT NM_000594
TNFR1 TCCTTCACCGCTTCAGAAAA GGGATAAAAGGCAAAGACCAA NM_001065
β-actin TCCTGACCCTGAAGTACCCCATTG GGAACCGCTCATTGCCGATAGT NM_001101
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(Cell Signaling Technology, USA), Fas, Fasl, (epitomics,
USA) and TNFR1 (Proteintech group,USA ) overnight at
4°C. Then followed by secondary antibody-conjugated
horseradish peroxidase (HRP) and detected by ECL solu-
tion .
ELISA assay for TNF-α secretion
After cells were treated with HCS for 4 h and 8 h, the level
of TNF-α protein accumulating in the medium were de-
termined using an TNF-α ELISA kit (ExCell Biology,
Shanghai, China). The assay was performed in duplicate
according to the manufacturer’s recommendations.
siRNA trasfection
siRNA targeted against Fas (5’- GUGCAAGUGCAAACC
AGACTT -3’), TNFR1 (5’- CAAAGGAACCUACUUGU
ACUU -3’), TNF-a (5’- GUGCUGGCAACCACUAA
GA -3’;) or control siRNA (5’-CCCCUUUUAAAA
GGGGCCC-3’) was transfected into T24 and EJ cells
using Lipofectamine RNAiMAX (Invitrogen) to a final
concentration of 50 pmol/ml according to the manu-
facturer’s recommendations. 48 hours after transfec-
tion, knockdown was assessed by PCR from a parallel
transfection.
Bladder cancer xenograft model and in vivo therapy
with HCS
All animal procedures were carried out with the ap-
proval of the Animal Ethics Committee of the Huazhong
University of Science and Technology. 4-week old fe-
male athymic nude mice (BALB/c-nu/nu mice) were in-
oculated subcutaneously with 5 × 106 T24 cells. After
7 days, 98% of mice grew visible tumors. The mice were
randomized and assigned to the control group or the ex-
perimental group. Mice in the control group were percu-
taneously injected with 0.4 ml saline daily, and mice in
the experimental group were percutaneously injected
with 0.4 ml HCS(1:2, 1:1) into the tumor every day. The
tumors were measured twice a week with microcalipers,
and the tumor volumes were calculated using the fol-
lowing equation: Tumor volume(mm3) = 1/2× (tumor
length) × (tumor width)2. And the body weight of the
mice was recorded twice a week. At the end of experi-
ment, tumors were excised, weighed, and then eachtumors were fixed in 4% of paraformaldehyde for fur-
ther analyses.In situ apoptosis detection by TUNEL staining
After desired treatment, the paraffin-embedded sections
of samples were studied by terminal deoxynucleotidyl
transferase-mediated dUTP nick-end-labeling (TUNEL)
assay. Staining was carried out according to the protocol
provided by the supplier. Apoptosis was evaluated by
counting the positive cells as well as the total number of
cells at 10 arbitrarily selected fields at 400× magnifica-
tion in a blinded manner.Immunohistochemistry staining
Immunohistochemistry (IHC) was conducted as previously
described [15]. Tissues were deparaffinized, rehydrated, and
incubated at room temperature in 0.3% H2O2 to block
endogenous peroxidase and in blocking solution for
nonspecific binding. Primary antibody were applied to
sections overnight at 4°C. Afterwards, tissues were in-
cubated with anti-mouse HRP conjugated (Abcam,
USA) secondary antibody for 1 h at room temperature.
Then enzyme development was performed with DAB/
H2O2 complex for 10 min at room temperature and in
the absence of light which provides a brownish precipi-
tation. The primary antibodies specific for Fas, Fasl
(epitomics, USA) ,TNF-α and TNFR1(Proteintech group,
USA) were used at working dilution 1:50, 1:100, 1:50
and 1:200 respectively. Stained (brown) cells were
quantified as number of positive cells. To evaluate the
intensity of antigen immunoreactivity we examined
the percent of positive staining urothelial cells in 10
fields at random per rat per antibody under 400 ×
magnification.Statistical analysis
Statistical analysis was performed using the software of
Statistical Package for the Social Sciences Version 16 for
Windows. Data from 3 to 5 independent experiments
were calculated as means and standard deviations. Com-
parisons of results between treated and control groups
were made by the Student t tests. A P-value of less than
0.05 was considered significant.
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HCS inhibits the viability of human bladder cancer cells
After cells were treated with various dilutions of HCS
for 24, 48 and 72 h, cell viability of T24 and EJ, mea-
sured by the MTS assay, decreased significantly in a
dose- and time-dependent manner (Figure 1A). Mean-
while, HCS showed little inhibition effect on less malig-
nant RT-4 cells and immortalized SV-HUC-1 cells. This
phenomenon indicated that HCS may have less damage
on normal bladder tissue.
Morphologic change induced by HCS
To get some detailed morphologic changes, we used
transmission electron microscopy. As shown in
Figure 1B, The normal cells (normal saline) showed
untreated cells with intact nuclear membrane, huge
and circular nuclei, more chromatin, abundant
mitochondria and endoplasmic reticulum with good
morphology. Compared with the control, the cells
treated with HCS for 24 h exhibited that the chro-
matin accumulation inside the nuclear membrane
lumped, a large number of autophagocytic vacuoles
formed, and the mitochondria were damaged. After
cells were incubated for 48 h, the cells became smaller, or-
ganelles were destroyed, partial nuclear membranes were
disrupted and nuclei broke up.Figure 1 HCS prohibited bladder cancer cells growth and induced ap
EJ, RT-4, and SV-HUC-1 cells. Values are given as a percentage of untreated
from a representative experiment; bars, SD. (B) The ultrastructural morphol
transmission electron microscope. (C) The apoptotic fraction of cells detect
after HCS treatments and the percentages showing the annexin V-positive/
independent experiments. *, p < 0.05 for HCS vs. control.Apoptosis effect of HCS on bladder cancer cells
The apoptotic effect of HCS on bladder cancer cells was
detected through Annexin V-FITC/PI double staining
assay. Results demonstrated that HCS had an effect on
increasing apoptosis. With Annexin V staining, early
apoptosis was clearly detectable in the two bladder can-
cer cells treated with HCS. Compared to the control
group, the cell apoptotic rates were significantly in-
creased in a dose-dependent manner (Figure 1C).
The effect of HCS on apoptosis-related molecules
To investigate the mechanism behind HCS-induced
apoptosis, we detected the level of several apoptosis-
related molecules by western blot. As is shown in
Figure 2, the results revealed that the levels of the ac-
tive (cleaved) forms of Caspase-3,-8,-9 and cleaved
PARP were increased in a dose-dependent manner in
HCS-treated T24 and EJ cells. We next determined
whether HCS-induced apoptosis in bladder cancer
cells is also associated with the modulation of the in-
hibitors of apoptosis proteins (IAPs) and Bcl-2 family
proteins. Western blotting results indicated that HCS
treatment decreased the expression of Bcl-2 and in-
creased the expression of Bax. The expression of
XIAP was also significantly decreased in both two cell
lines after HCS treatment.optosis of T24 and EJ cells. (A) Effect of HCS on proliferation of T24,
control cells. The data are presented as the average for triplet results
ogic changes of the T24 cells treated with HCS (1:100) under the
ed by annexin V staining (x-axis)/propidium iodide staining (y-axis)
PI-negative fraction. Columns are expressed as mean ± SD of 3
Figure 2 Effect of HCS on the levels of apoptosis-related molecules in T24 and EJ cell lines. The active (cleaved) forms of Caspase 3,8,9
and cleaved PARP were increased in a dose-dependent manner in HCS-treated T24 and EJ cells. the expression level of Bax was also elevated,
whereas, the anti-apoptosis proteins such as Bcl-2 and XIAP were down regulated after HCS treatment.
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To explore the underlying molecular signaling pathways
by which HCS exerts antitumor effects, we examined
the expression of Fas/Fasl and TNF-α/TNFR1 by PCR,
western blot immunohistochemistry and ELISA. As is
shown in Figure 3A, B, the mRNA levels of Fas, Fasl,Figure 3 HCS treatment upregulated the expression of Fas, Fasl and T
EJ (B) cells after HCS treatment. (C) Quantification of TNF-α in conditioned
TNFR1 in T24 and EJ cells after HCS treatment were detected by western bTNF-α were increased in a dose-dependent manner in
the two cell lines after HCS treatment. Furthermore,
Western blotting results indicated that HCS treatment
also increased the protein levels of Fas and Fasl, and
ELISA results showed HCS could stimulate cells secrete
TNF-α (Figure 3C, D). On the other hand, the expressionNF-α. The mRNA levels of Fas, Fasl, TNF-α and TNFR1 in T24 (A) and
cell supernatant using ELISA. (D) The protein levels of Fas, Fasl and
olt. *, P < 0.05 vs control group.
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changes after HCS treatment as shown in Figures 3 and 4.
HCS induced cell death is mediated by Fasl/Fas and
TNF-α/TNFR1 pathway
To determine whether Fas/Fasl and TNF-α/TNFR1 ex-
pression is critical for the effect of HCS on bladder can-
cer cells, we knocked down TNF-a, TNFR1, Fas by
siRNA or inhibited binding of FasL to its receptor by a
blocking antibody (ZB4) prior to the addition of HCS,
and then detected the cell viability. First, we confirmed
that the siRNA effectively reduced the TNF-a, TNFR1,
Fas mRNA level in T24 and EJ cells (Figure 5D, E). Then
we found that TNF-a, TNFR1, Fas knockdown and the
use of ZB4 significantly decreased the effect of HCS on
cell proliferation compared with the control groups
(Figure 5F, G). Furthermore, the effect of HCS on cell
proliferation was more decreased by both of TNF-a/
Fas siRNA and TNF-a siRNA/ZB4 treatment, which
implicated both Fas/Fasl and TNF-α/TNFR1 as media-
tors of HCS-induced cell death.
Activation of NF-κB pathway against HCS induce cell
death
We also detected the activation of NF-κB pathway in
T24 and RT-4 cells treated with HCS. Western blottingFigure 4 HCS induced cell apoptosis and the expression of Fas, Fasl a
tumor sections and immunohistochemical analysis of Fas, Fasl, TNF-α and T
Columns are expressed as mean ± SD of five samples of each group. *, P <results showed HCS treatment decreased the expression
of iκB-α and increased the expression of p-p65 in a
dose-dependent manner, which indicated NF-κB path-
way was activated by HCS (Figure 5A). To investigate
whether NF-κB pathway got involved in HCS induced
cell death, we tried inhibiting NF-κB activity with PDTC
before HCS treatment, then we compared the cell viabil-
ity with that of HCS treated alone. Interestingly, when
we pretreated T24 and RT-4 cells with NF-κB inhibitor
PDTC for 1 h before HCS treatment, the effect of
HCS on the cell proliferation was strongly enhanced
(Figure 5B, C). The results demonstrated that NF-κB
pathway could attenuated the effect of HCS on bladder
cancer cell growth.
HCS inhibits human bladder tumor xenograft growth in
athymic nude mice
We further investigated the effect of HCS on a trans-
planted tumor growth produced by T24 cells. Only two
mice did not survive at the end of the experiment. As
shown in Figure 6, the growth of T24 tumor xenografts
was inhibited significantly following the injection of
HCS at the dose levels of 1:2 and 1:1. The average body-
weight of the control group drops much more than the
treatment groups (P < 0.05), and it’s speculated that the
rapidly lose of bodyweight of the control mice maynd TNF-α in vivo. Representative results of the TUNEL staining of
NFR1 expression in control and HCS-treated T24 cell-transplanted mice.
0.05 compared to the control group.
Figure 5 The role of Fasl/Fas, TNF-α/TNFR1 and NF-κB pathway in HCS induced apoptosis. (A) The protein levels of iκB-α , p65 and -p65 in
T24 and EJ cells after HCS treatment were detected by western bolt. (B, C) Proliferation of cells treated with HCS(1:100) after inhibition of NF-κB
pathway by PDTC. siRNA interference effects was tested through PCR in T24 and EJ cell lines (D, E). Proliferation of T24 (F) and EJ (G) cells treated
with HCS(1:100) after inhibition of Fasl/Fas and TNF-α/TNFR1 by siRNA or ZB4. *, P < 0.05.
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the average tumor masses in the control mice were
nearly 2 fold (P < 0.05) greater than that of HCS-treated
mice(1:1), while there is no significant difference be-
tween the two HCS treatment group (P > 0.05). The
apoptosis of tumor cells was evaluated using TUNEL
stain. The apoptotic cells were more prominent in the
HCS-treated tumors than that of the control tumors as
is seen in Figure 4. Then We detected the expression of
Fas, Fasl, TNF-α and TNFR1 by IHC , and the increases
in protein level of Fas, Fasl, TNF-α were also observed
in the tumors of HCS-treated mice.
Discussion
In recent years, the search for alternative anticancer
agents in traditional medicine has been a potential strat-
egy [16,17]. In this study, we explored that HCS inducesapoptosis not only in cell culture, but also in tumor cells
in vivo, as demonstrated in bladder cancer xenograft
model treated with non-toxic dilutions of HCS.
To reveal the effect of HCS on bladder cancer cell
lines, we tested the effect of HCS on cell growth and
apoptosis. As revealed by MTS assay, HCS possessed an
inhibitory ability on cell viability in a dose-dependent
manner, while the inhibition is less remarkable in less
malignant RT-4 and SV-HUC-1 cells. This phenomenon
indicated that HCS may have less damage on normal
bladder tissue. Furthermore, the morphologic changes
induced by HCS indicate that cells were undergoing
apoptosis. With annexin V/PI staining, HCS treatment
significantly increased the proportion of apoptotic cells,
which is increased with the rise of the concentration.
These results confirmed that HCS exhibited an evident
apoptosis-inducing effect on bladder cancer cells.
Figure 6 HCS inhibited tumor growth in vivo. Mean of tumor volume (A), body weight of mice (B) and tumor weight (C) measured at the
indicated number of days after mice were treated with HCS. (D) Representative pictures of tumor in control and HCS-treated T24 cell-transplanted
mice. *, P < 0.05 compared to the control group.
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an essential role in apoptosis. Caspases are first synthe-
sized as inactive pro-Caspases and regulated at a post-
translational level. Activated Caspases eventually lead
to apoptotic cell dismantling [18]. Poly (ADP-ribose)
polymerase (PARP), a family of proteins involved in a
variety of cellular processes including DNA repair
and programmed cell death, is a downstream target
of Caspase-3 [19,20]. Inhibitors of apoptosis proteins
(IAPs) and Bcl-2 family proteins have also been
shown to be important in the regulation of apoptosis
[21,22]. We therefore tested the expression of Bax,
Bcl-2, XIAP, cleaved PARP, cleaved Caspases 3, 8, 9,
all are important members involved in apoptosis,
through western blot after HCS treatment. The re-
sults confirmed that the apoptosis induced by HCS
was related with the changes of these protein expres-
sion. So, what actually activated the Caspase cascade
and initiated the apoptosis in bladder cancer cells
treated with Huachansu? We tried to explore the re-
sult from both the intrinsic and extrinsic apoptosis
pathway. The mitochondria-initiated intrinsic path-
way, in which the release of cytochrome c from the
mitochondrial matrix following loss of inner mito-
chondrial membrane integrity triggers formation of
the apoptosome composed of Apaf-1, pro-Caspase-9,
dATP, and cytochrome c [23]. The death receptor-
initiated extrinsic pathway is another apoptosis process,
in which death receptor ligation is followed by recruit-
ment of adaptor molecules and activation of Caspase-8 orCaspase-10 [24,25]. We failed to detect the expression of
cytochrome c by western blot for several times (data not
shown), while the expression of Fas, Fasl, TNF-α were all
elevated at both mRNA and protein level after HCS
treatment. This results prompt us that the death
receptor-initiated extrinsic pathway may contribute to
the apoptosis induced by HCS in bladder cancer cells.
Fas is a member of the death receptor family, a sub-
family of the tumor necrosis factor receptor superfamily.
Binding to Fas by its physiological ligand, FasL, results
in recruitment of adaptor molecules and activation of
Caspase-8 or Caspase-10, to form death inducing signal-
ing complex (DISC), transducing a downstream signal
cascade resulting in apoptosis [26,27]. TNF-α is a pleio-
tropic ligand of tumor necrosis factor receptor 1 and 2
(TNFR1 and TNFR2) that can signal both cell survival
and cell death [28,29]. The death-inducing complex
assembles following internalization of the TNFR1 and
consists of TNFR1-associated death domain protein
(TRADD) and receptor-interacting protein kinase 1
(RIPK1), which then recruit Fas-associated protein with
death domain (FADD) and Caspase-8 to generate the
DISC [30]. In this study, to determine whether TNF-a/
TNFR1 and Fas/Fasl is required for HCS-induced cell
death, we knocked down TNF-a, TNFR1, Fas by siRNA
or inhibited binding of FasL to its receptor by a blocking
antibody prior to the addition of HCS, then detected the
cell viability. Importantly, downregulation of TNF-a,
TNFR1, Fas or inhibition of Fas/Fasl interaction de-
creased the relative number of death cells induced by
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knockdown with respective siRNA decreased the apop-
tosis rate induced by HCS in T24 cells, and the expres-
sion of cleaved caspase-3,-7,-8 and cleaved PARP also
decreased as is shown in Additional file 1: Figure S1. Be-
cause of the above results we can conclude that HCS in-
deed affects bladder cancer cell growth which is mediated
by TNF-a/TNFR1 and Fas/Fasl signaling pathway.
A major finding of this paper is that HCS not only re-
duced cell proliferation in cell culture but also inhibited
tumor growth in vivo. We observed a significant increase
in TUNEL-positive apoptotic cells in tumors from
mice that were treated with HCS, and the protein level
of Fas, Fasl, TNF-α in HCS-treated tumors were also
up-regulated.
As we knew,the resistance of cells to TNF-α mediated
apoptosisis attributed to TNF-α induced NF-κB activa-
tion [31], then we detected the activation of NF-κB path-
way. As expected, NF-κB pathway was activated after
HCS treatment. Then, we found inhibiton of NF-κB by
the inhibitor could enhance the effect of HCS-induced
cell death. The results indicated that the treatment of
HCS plus chemotherapeutic drugs which could inhibit
NF-κB pathway in bladder cancer may have better cura-
tive effect compared to monotherapy.Conclusions
Taken together, our study demonstrated that HCS
induced-apoptosis in human bladder cancer was medi-
ated by the activation Fas/Fasl and TNF-α/TNFR1.
HCS may proved to be novel therapeutic strategy in
the inhibition of carcinogenesis and progression of
bladder cancer. Nevertheless, further studies are re-
quired to verify whether HCS could be used for an
intravesical treatment.Additional file
Additional file 1: TNF-a, TNFR1 and Fas siRNA transfection inhibited
apoptosis of T24 cell induced by HCS. T24 cells are treated with TNF-a,
TNFR1 and Fas siRNA for 48 h before HCS(1:100) treatment, And the
apoptotic rate was detected by flow cytometry ,the expression of cleaved
PARP, XIAP and cleaved caspase-3,-7,-8 was detected by western blot.
Additional file 1: Figure S1 (A,B) TNF-a, TNFR1 and Fas knock down decreased
the apoptosis rates of HCS induced apoptosis in T24 cell, Columns are
expressed as mean ± SD of 3 independent experiments. *, p < 0.05 for HCS
vs. control, #, p < 0.05 for positive siRNA vs. negative siRNA and control +
HCS. HCS, huachansu (1:100). (C) The expression of cleaved caspase-3,-7,-8
and cleaved PARP was decreased whereas the expression of XIAP elevated
compared to the negtive control after respective siRNA transfection. Lane 1,
2, 3, 4, 5, 6 is consistent with the group order of that in Figure S1 B.Abbreviations
HCS: Huachansu; TNF- a: Tumor necrosis factor- a; TNFR1: Tumor necrosis
factor receptor 1; NF-κB: Nuclear factor kappa B; IAPs: Inhibitors of apoptosis
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